BMY - Bristol-Myers Squibb Company
| Previous Close | 66.87 |
| Open | 66.39 |
| Bid | 64.15 x 1000 |
| Ask | 64.20 x 1800 |
| Day's Range | 63.60 - 66.74 |
| 52 Week Range | 42.48 - 68.34 |
| Volume | 21,927,225 |
| Avg. Volume | 18,616,233 |
| Market Cap | 150.403B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | 18.54 |
| EPS (TTM) | 3.46 |
| Earnings Date | Feb 05, 2020 |
| Forward Dividend & Yield | 1.80 (2.69%) |
| Ex-Dividend Date | Jan 01, 2020 |
| 1y Target Est | 71.90 |
- Simply Wall St.
Are You An Income Investor? Don't Miss Out On Bristol-Myers Squibb Company (NYSE:BMY)
Dividend paying stocks like Bristol-Myers Squibb Company (NYSE:BMY) tend to be popular with investors, and for good...
- Zacks
Here is Why Growth Investors Should Buy Bristol-Myers (BMY) Now
Bristol-Myers (BMY) could produce exceptional returns because of its solid growth attributes.
- Zacks
What Lies Ahead for Healthcare ETFs in Q4 Earnings?
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
- Zacks
Roche's Urothelial Cancer Study on Tecentriq Disappoints
Roche's (RHHBY) study on Tecentriq in muscle-invasive urothelial cancer fails to meet goals.
- Zacks
Zacks.com featured highlights include: SNX, ICHR, TECD, NSIT and BMY
Zacks.com featured highlights include: SNX, ICHR, TECD, NSIT and BMY
- Zacks
Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings?
Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.
- Zacks
J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children
Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.
- Zacks
Want To Retire Early? Learn the Intelligent Investing Secret - January 24, 2020
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
- GuruFocus.com
Gilead, Bristol-Myers Pumped More Into R&D Than Shareholder Enrichments
Many other members of Big Pharma spent more on dividends and stock buybacks, a strategy some view as shortsighted Continue reading...
- Bloomberg
Index Fund Giants Draw Antitrust Scrutiny in U.S. Mergers
U.S. antitrust officials have begun asking companies about communications with their biggest shareholders as part of merger investigations.
- Barrons.com
Amgen Stock Is Poised to Gain in 2020, Analyst Says. Here’s Why.
(AMGN) could have a strong year as the turbulence of 2019 fades into the rearview, according to a Wednesday afternoon note by Citi analyst Mohit Bansal. Bansal, who rates the stock a Buy, increased his price target to $275 per share from $245. “We think in 2020 the company could do more than just catching up with the Nasdaq Biotechnology Index as the setup looks even better this time versus 2019,” he wrote.
- Zacks
Bristol-Myers Squibb (BMY) Flat As Market Gains: What You Should Know
Bristol-Myers Squibb (BMY) closed at $67.43 in the latest trading session, marking no change from the prior day.
- Zacks
Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza
Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.
- Zacks
The Extreme Risks of Trading Your Own Retirement Assets - January 22, 2020
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
- Zacks
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
Smart Beta ETF report for EUSA
- Zacks
5 Stocks Near a 52-Week High That Can Scale Higher
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
- Zacks
Top Ranked Momentum Stocks to Buy for January 21st
Top Ranked Momentum Stocks to Buy for January 21st
- Zacks
Should Value Investors Buy Bristol-Myers Squibb (BMY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
BMY or AZN: Which Is the Better Value Stock Right Now?
BMY vs. AZN: Which Stock Is the Better Value Option?
- Benzinga
9 Takeaways From The JPMorgan Healthcare Conference
The JPMorgan Healthcare Conference, which showcases innovations in the industry and provides a platform to exchange ideas and insights as well as to make breaking announcements, went by without much fanfare ...
- Zacks
Is Bristol-Myers Squibb (BMY) a Good Stock to Pick Now?
Is Bristol-Myers Squibb (BMY) a great pick from the value investor's perspective right now? Read on to know more.
- Zacks
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
- MoneyShow
Top Picks 2020- Bristol-Myers Squibb BMY
With politicians on both sides of the aisle calling for drug price controls, and a number of the Democratic candidates calling for "Medicare for all," it has been a challenging environment for a host of medical sectors, suggests income expert Chuck Carlson, editor of DRIP Investor.
- Zacks
J&J Seeks Label Expansion for Spravato Nasal Spray in EU
J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.
- Zacks
Zacks.com featured highlights include: Genesco, GreenTree Hospitality, Bristol-Myers Squibb, Barclays PLC and Valero Energy
Zacks.com featured highlights include: Genesco, GreenTree Hospitality, Bristol-Myers Squibb, Barclays PLC and Valero Energy
